The patent play: Biogen gets a PhIII boost for its bit-better take on the blockbuster MS franchise drug Tecfidera Endpoints News
Wellington Partners tanks up with $237M for its next life sci fund — same strategy, but with more cash on hand. A year ago, when Philadelphia-based Carisma …